Arima Genomics

Executive Summary

Arima Genomics is a private biotechnology company that leverages proprietary Hi-C technology to provide comprehensive 3D genomic insights. Its platform integrates sequence and structural information from any genome, enabling discoveries in cancer diagnostics, epigenetics, and genome assembly. The company offers products, services, and a CLIA-certified clinical test aimed at accelerating research and improving patient care. With a focus on unraveling the three-dimensional architecture of genomes, Arima Genomics addresses critical needs in understanding gene regulation, genomic rearrangements, and structural variants that are often missed by traditional sequencing. The company's technology has potential applications in oncology, rare diseases, and agricultural genomics, positioning it as a key enabler in the rapidly growing field of spatial genomics. Despite being privately held and without disclosed financials, Arima Genomics has established collaborations and a growing customer base among academic institutions and pharmaceutical companies. The conviction score of 70 reflects its innovative technology and potential market impact, tempered by the lack of public financial and operational data.

Upcoming Catalysts (preview)

• Q4 2026Launch of a next-generation clinical cancer diagnostic test based on Hi-C technology70% success
• Q2 2026Publication of landmark study demonstrating Hi-C utility in liquid biopsy80% success
• Q3 2026Strategic partnership with major pharmaceutical company for oncology biomarker discovery60% success